Georg Aue, Margaret A. Lindorfer, Paul V. Beum, Andrew W. Pawluczkowycz, Berengere Vire, Thomas Hughes, Ronald P. Taylor, Adrian Wiestner. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95(2):329-332; https://doi.org/10.3324/haematol.2009.012484.